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Abstract
Immunohistochemical examination showed that sections of intimal atherosclerotic plaques contained cells and cell
clusters as well as areas of extracellular matrix specifically stained with antibodies against ganglioside GM3. No
immunohistochemical staining was observed in areas bordering the plaques where there was no histological evidence of
atherosclerosis. To determine whether the ganglioside GM3 deposits in the intimal plaques derived directly from plasma or
were synthesised by intimal cells, intimal plaque and plasma LDL were assayed for ganglioside GM3 fatty acid
composition. This assay showed that more than 50% of the fatty acids of GM3 isolated from both atherosclerotic and
normal intima are either minor fatty acids or those absent from LDL GM3. We conclude that the GM3 deposits present in
intimal plaque arise in intimal cells and do not derive from plasma LDL. q 1997 Elsevier Science B.V.
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1. Introduction
A major feature of atherosclerosis is an increase in
the lipid content of the arterial wall. Most pro-
nounced is an increased cholesterol concentration,
especially cholesteryl esters, but there are also
changes in the concentration and composition of all
w xlipid classes. Our previous findings 1,2 as well as
w xdata from other investigators 3–7 demonstrated a
significant increase in the content of gangliosides and
changes in their composition when atherosclerotic
lesions of human aortic intima were compared with
normal intima.
) Corresponding author. Fax: q7-95-4152962.
How the main lipid classes accumulate and lo-
calise in atherosclerotic lesions has been extensively
w xinvestigated 8,9 . In contrast, the accumulation of
gangliosides in atherosclerotic lesions has been little
studied and their origins are unclear. In particular, it
is unknown whether gangliosides in plaques are de-
rived from plasma or whether they form through
metabolic processes in the intima.
In the present study we used polyclonal antibodies
raised against ganglioside GM3 to investigate gan-
glioside accumulation in tissue sections prepared from
human arterial atherosclerotic lesions and normal in-
tima. To determine whether ganglioside GM3 in
atherosclerotic plaques derived directly from the
plasma or were synthesised in situ, both athero-
0925-4439r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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sclerotic plaques and unaffected intimal areas were
assayed for their ganglioside fatty acid compositions.
These assays were compared to analogous composi-
tions of LDL taken from healthy donors and patients
with hypercholesterolaemia.
2. Materials and methods
The present investigation conformed with the prin-
w xciples outlined in the Declaration of Helsinki 10 .
2.1. Tissues
For ganglioside fatty acid analysis, thoracic aortas
from 40–60 year old men and women who had died
of myocardial infarction were obtained at autopsy
within 3 h of sudden death. The atherosclerotic le-
 .sions mainly plaques occupied about half the total
inner surface of the aortas. The intima was mechani-
cally separated from the media along the secondary
w xinternal limiting membrane as described earlier 11 .
Grossly normal areas three specimens from each
.aorta, 1–1.5 g wet tissue and uncomplicated plaques
 .four specimens from each aorta, 1–2 g wet tissue
were excised.
For immunohistochemistry, arterial segments from
9 aortas and 14 carotid arteries were obtained from
patients whose ages ranged from 38 to 69 years. The
aortic specimens were obtained during aortic recon-
struction and the carotid artery specimens by en-
darterectomy. These arterial segments included
atherosclerotic lesions with adjacent macroscopically
normal areas. Arterial samples were embedded in an
OCT compound, rapidly frozen in liquid nitrogen and
stored at y708C until cryostat sectioning.
2.2. Low density lipoproteins
 .Human LDL ds1.019–1.063 grml were ob-
tained by sequential ultracentrifugation as described
w xearlier 12 from the fresh plasma of normal volun-
 .teers average serum cholesterol, 2.2 mgrml and the
plasma of patients with hypercholesterolaemia aver-
.age serum cholesterol, 4.2 mgrml which were taken
during plasmapheresis.
2.3. Extraction and analysis of lipids
The aortic tissues were homogenised and extracted
w xwith chloroformrmethanol 13 . Lipid extraction of
LDL and the quantitative determination of lipid phos-
phorous and total cholesterol were carried out as
w xdescribed earlier 14,15 .
GM3 was isolated by alkaline treatment of lipid
extracts, dialysis and chromatography on DEAE-Sep-
 .hadex A-25 Pharmacia, Sweden with TLC monitor-
w xing as described earlier 1 . Quantitative determina-
tion of the total gangliosides was carried out accord-
w xing to the Svennerholm method 16 .
Fatty acid methyl esters were prepared by acid
methanolysis of GM3 followed by extraction with
hexane and separation by gas chromatography using
a methyl silicone capillary column 12 m=0.2 mm
. w x=0.33 mm 1 . The initial oven temperature was
maintained at 1508C for 1 min and then increased at a
rate of 108Crmin until 2208C was reached. Gas
chromatographyrmass spectrometry analysis was
performed on a Hewlett-Packard 5890 gas chromato-
graph with HP5970B mass-selective detector. Methyl
esters of margarinic acid were used as an internal
standard.
The results were expressed as means"SE. Statis-
tical evaluation of the data was performed by the
Student’s t-test with a value of p-0.05 being con-
sidered significant.
2.4. Characterisation of anti-GM3 antibodies
Anti-GM3 serum was obtained in our laboratory
by 2–5 immunisations of rabbits with human liver
GM3-methylated BSA conjugate. Fatty acid composi-
tion of human liver GM3 was: 16:0–10%, 18:0–6%,
18:1–1%, 20:0–5%, 22:0–32%, 22:1–3%, 23:0–9%,
w x24:0–19% and 24:1–15% 15 .
An immunoglobulin fraction with GM3-binding
activity was isolated by affinity chromatography on
 .an octyl-Sepharose CL 4B Pharmacia, Sweden
coated with human liver GM3. The column was first
washed with 0.01 M PBS, pH 7.4 and 1 M NaJ in
PBS. The anti-GM3 antibodies were eluted with 3 M
w xNaSCN in PBS 17 .
The activity and specificity of anti-GM3 immuno-
globulins were tested by ELISA as described earlier
w x18 . The antigen specificity of anti-GM3 was studied
using GM1, GD1a, GD1b and GT1b gangliosides
from bovine or human brain prepared in our labora-
tory. The amount of each ganglioside in the mi-
crotiter well was 1 nmol. Concentrations of anti-GM3
( )Y.V. Bobryshe˝ et al.rBiochimica et Biophysica Acta 1361 1997 287–294 289
 .antibodies and control rabbit g-globulins Sigma
were 2.5 and 5.0 mgrml. The binding of anti-GM3
antibodies to GM3 from human liver and aorta was
about threefold higher than with other tested ganglio-
 .sides. Rabbit g-globulins Sigma used as a negative
control showed low binding levels to GM3 and other
gangliosides studied.
2.5. Immunohistochemistry
Sections of arterial wall were cut at 5–7 mm
thickness, air dried for 45 min and then fixed in
acetone for 10 min. After elimination of endogenous
peroxidase activity by 1% hydrogen peroxide for 5
min, the sections were tested by the ABC method
w x w x19 as previously described 20 . In brief, the sec-
tions were incubated for 60 min with anti-GM3-anti-
 .bodies 100 mgrml . After washing in Tris-phos-
 .phate buffered saline TPBS, pH 7.4, 10 min the
sections were incubated for 20 min with a biotin-
labeled secondary antibody goat anti-rabbit-VEC-
.TOR BA-1000 . The sections were then washed in
PBS for 5 min and the avidin–biotin complex
 .ELITE-ABC, VECTOR PK61000 was added for 30
min. After washing for 10 min in TPBS, brown
staining was produced by a 5 min treatment with
X  .3,3 -diaminobenzidine DAB . All the incubations
were completed at room temperature. For negative
controls, the first antibody was omitted or the sec-
tions were treated with an immunoglobulin fraction
 .of non-immune goat serum VECTOR S-1000 as a
substitute for the primary antibody. None of the
negative control sections showed positive immune
staining. Counterstaining was performed with Mayer’s
haematoxylin.
3. Results
3.1. Ganglioside localisation in intimal athero-
sclerotic plaques
Immunohistochemical examination clearly demon-
strated that sections of intimal atherosclerotic plaques
contained cells and cell clusters as well as areas of
extracellular matrix specifically stained with antibod-
ies against ganglioside GM3. Staining with anti-GM3
antibodies was found in atherosclerotic plaques from
 .  .both aortas Fig. 1a–c and carotid arteries Fig. 1d .
Intimal areas without any histological signs of athero-
sclerosis which were adjacent to the lesions did not
 .stain with the antibodies Fig. 1d . Binding of anti-
GM3 antibodies within the atherosclerotic plaques
was irregular with areas manifesting intense staining
bordering on areas without staining. The intensity of
anti-GM3 antibody binding with the cells varied and
was usually stronger in cells which formed clusters
 .than in single cells Fig. 1a . Antibody-positive cell
clusters were observed more often than antibody-
positive single cells, the majority of which looked
 .like foam cells Fig. 1b . It was apparent that not
only cells, but the extracellular matrix also was
specifically stained with anti-GM3 antibodies Fig. 1c
.and d . The extracellular matrix was usually diffusely
stained. Diffuse extracellular binding of GM3-anti-
body was detected in all atherosclerotic plaques but
large extracellular GM3 positive deposits with a di-
ameter no less than 50 mm were also found in
 .atherosclerotic plaques in one aorta Fig. 1c and in
 .five carotid arteries Fig. 1d . The matrix areas bind-
ing anti-GM3 antibodies often surrounded cholesterol
 .crystals Fig. 1b .
3.2. Lipids of aortic intima and LDL
To characterise the intima and plasma specimens
we assayed their lipid composition. The content of
cholesterol, phospholipid and ganglioside concentra-
tions in intimal atherosclerotic lesions amounted to
28.9"7.01, 8.55"1.2 and 0.161"0.03 mmolrg
wet tissue, respectively. The content of these compo-
nents in unaffected intima were 12.7"3.0, 5.7"0.9
and 0.046"0.01 mmolrg wet tissue, respectively.
This data is similar to that of other investigators
w x3,4,8,9 .
The content of gangliosides in plasma LDL of
hypercholesterolaemic patients and healthy donors
did not differ significantly 4.1 and 4.2 nmolrmg of
.protein, respectively which is similar to the findings
w xof others 14 .
3.3. GM3 fatty acid composition
To determine whether ganglioside GM3 deposits
in intimal plaques originate from plasma or are syn-
thesised by plaque cells in situ, we assayed athero-
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Table 1
Fatty acid composition of GM3 ganglioside from normal and
atherosclerotic aorta intima and LDL of healthy donors and
 .patients with hypercholesterolaemia mean"SE
Fatty acids LDL Aortic intima
patient donor lesions unaffected
 .  .  .  .ns3 ns2 ns4 areas ns3
14:0 4"2 1"0.4 tr. 1"0.2
16:0 39"9 40"2 14"1 9"1
18:2 10"3 6"1 5"1 7"1
18:1 20"3 28"4 5"1 5"1
18:0 19"5 18"4 8"2 7"2
20:0 1"0.3 1"0.2 1"0.3 3"0.5
22:0 1"0.5 0.5"0.1 11"2 15"2
23:0 2"0.4 0.5"0.05 8"1 7"1
24:0 — — 20"5 17"4
24:1 — — 23"8 16"4
Other 4"1 5"2 5"1 13"3
sclerotic intimal samples and plasma LDL for their
GM3 fatty acid composition. There were no differ-
ences in the fatty acid compositions of GM3 in
plasma LDL when the normal and hypercholesterol-
 .aemic groups were compared p-0.001 . In GM3
from the intimal plaques, the contents of palmitic
 .acid 16:0 and 24:1 acids were approximately 1.5-
fold higher than in GM3 from the uninvolved areas
 .while the content of 22:0 acid was lower Table 1 .
There were, however, considerable differences in
the fatty acid composition of GM3 from the intima
and from LDL. Palmitic acid was the most common
fatty acid found in LDL GM3 while the actual con-
tent of this acid was relatively low in intimal ganglio-
 .  .  .sides. Stearic 18:0 , oleic 18:1 and linoleic 18:2
acids accounted for 50% of GM3 fatty acids in LDL.
In the intima, these made up about 20% of GM3 fatty
 .acids while C22–24 acids saturated and monoenic
were the highest, constituting 62 and 55% of fatty
acids in GM3 from plaques and uninvolved areas,
respectively. In LDL GM3, these long chain fatty
acids were only minor components or were practi-
 .cally absent Table 1 .
4. Discussion
Considerable attention has been directed to how
human vascular wall gangliosides accumulate in
atherosclerotic lesions. The content and composition
of these functionally important components of cells
and the extracellular matrix has been studied by
w xchemical and immunological methods 1–7 but the
origin of ganglioside deposits and where they localise
in atherosclerotic lesions remain unclear. The present
study shows that the ganglioside GM3 accumulation
in intimal atherosclerotic plaques is both intracellular
and extracellular.
Atherosclerotic plaques represent areas of lipid
storage usually associated with elevated plasma LDL
and increased influx of lipids into the arterial wall.
GM3 is the major ganglioside in all extraneural tis-
sues including the intima. GM3 comprises 66% of
gangliosides in normal intima, 93% of gangliosides in
w xatherosclerotic intima 1,2 and 45% of gangliosides
w xin human plasma LDL 21 . Whether GM3 accumu-
lates in plaques because of a significantly higher
w xinflux of LDL in atherosclerotic intima 22–24 or
because of changes in local ganglioside metabolism
and trafficking in atherosclerotic intimal cells, is not
known.
w xThe data of Kundu et al. 25 on human plasma
gangliosides and our findings concerning the struc-
w xture of gangliosides in the human aortic intima 1 ,
highlight considerable differences between the fatty
acid composition of plasma and intimal GM3. We
hypothesised that a comparison of the fatty acid
composition of GM3 isolated from normal intimal
areas and atherosclerotic plaques with that of GM3
from plasma LDL of both healthy subjects and hyper-
cholesterolaemic patients would help elucidate the
origin of GM3 deposits in atherosclerotic intima. Our
study showed no differences in the fatty acid compo-
sition of LDL GM3 from donors and patients, which
w xagrees with the findings of Kundu et al. 25 . The
higher palmitic acid content of GM3 isolated from
 .  .  .Fig. 1. GM3-positive staining of atherosclerotic intima in the aorta a–c and carotid artery d . a Large arrows show GM3-positive
 .cells. Small arrows show GM3-negative cells in atherosclerotic intima. b Large arrows show GM3-positive cells which appear to be
 .foam cells. Outlined arrows indicate the association of GM3 with cholesterol clefts which are marked by stars. c Focal and diffuse
 .locations of specific deposits of GM3-positive in the extracellular matrix are shown by small and large arrows, respectively. d Focal
locations of specific deposits of GM3-positive in the extracellular matrix are shown by arrows. ABC immunoperoxidase technique,
counterstaining with Mayer’s haematoxylin. Original magnification: =400.
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atherosclerotic plaques in comparison with normal
.intima may be due to influx from the plasma. How-
 .ever, most fatty acids )50% of GM3 in athero-
sclerotic and normal areas of intima represented
C22–24 acids which are virtually absent from LDL
GM3. These differences imply that GM3 deposits in
atherosclerotic intima are of local cell origin. This
conclusion is supported by the fact that in contrast to
 .other lipids phospholipids and cholesteryl esters ,
there is no exchange of fatty acid in the ceramide
moiety of gangliosides. No enzymes capable of cleav-
ing fatty acid from whole ganglioside molecules have
been identified. Some cell types are said to contain
very small amounts of lysogangliosides 0.1% of the
. w xtotal ganglioside content 26 .
Nevertheless, influx of LDL may be involved in
the accumulation of GM3 in the intima. Chatterjee et
w xal. 27 showed that in proximal tubular cells from
LDL receptor-negative subjects, LDL stimulated the
synthesis of lactosylceramide, a precursor of GM3
and the effects of LDL were not related to their
glycosphingolipid content. Metabolic studies with ex-
ogenous gangliosides labeled by sphingosine also
showed that ceramide can be utilised by cells for the
w xsynthesis of their own gangliosides 28 .
Our immunohistochemical findings show that inti-
mal atherosclerotic plaques contain cells intensively
reacting with anti-GM3 antibodies as well as anti-
body-negative cells. In the areas bordering athero-
sclerotic plaques without histological signs of athero-
sclerosis, the intimal cells did not react with anti-GM3
antibodies. Three possibilities might explain this phe-
nomenon. First, the GM3 content might be higher in
immunoreactive cells than in immunonegative cells.
Second, GM3 at the surface of the immunoreactive
cells might be more highly exposed and its organisa-
tion in the membrane might be unique for immunore-
active cells compared with GM3 in immunonegative
cells. Third, the immunoreactive cells might belong
to a cell type absent from uninvolved areas.
The first explanation is supported by our previous
finding that the GM3 content is higher in cells from
atherosclerotic lesions cells than in cells from normal
w xareas 2 . The second possibility is consistent with the
w xdata of other authors 29–31 : GM3 is found in
virtually all types of cells and tissues but only those
cells with a relatively high content of GM3 show
positive immunoreactivity with anti-GM3 antibodies.
Furthermore, since there is a threshold concentration
of GM3 exposed at the cell surface, a high concentra-
tion of GM3 in the plasma membrane may induce a
novel conformational change that is recognised by
anti-gangliosides. The third possibility cannot be ex-
cluded but we did not determine the type of GM3-
positive cells in this study. Judging from their lipid
inclusions, some of the GM3-positive cells appeared
to be foam cells but their origin was not established.
Comparing the fatty acid compositions of GM3
from atherosclerotic intima with that from LDL sug-
gests that the extracellular matrix-bound gangliosides
are also of local cell origin. Significant amounts of
gangliosides are contained in the substrate-attached
w xmaterial of cultured cells 32,33 as well as in the
w xculture medium 34 . The appearance of gangliosides
in the extracellular space might relate to plasma
membrane shedding, a process which can be charac-
terised as exfoliation of whole portions of the plasma
membrane into the extracellular environment. This
fragmentation is likely to affect the most rigid do-
mains of the plasma membrane. Apical membranous
fragments have the highest cholesterol content and
thus are highest in lipid microviscosity which makes
these fragments more prone to shedding than other
w xareas of the membrane 35 . GM3 and higher ganglio-
sides are localised in the outer surface of the plasma
membrane and often occupy the apical areas. Cells
from atherosclerotic intima contain an increased
cholesterol:phospholipid ratio in comparison to nor-
mal cells which makes their membranes even more
w xrigid 8 . Shedding might be a way of removing rigid
lipids from the cell surface and this process might
occur through the formation of microvesicles from
the plasma membrane. Exfoliation of the apical mem-
branous fragments containing gangliosides is thought
to occur in many different normal and neoplastic
w x w xcells 35–37 . Li et al. 38 related shedding to cellu-
lar ganglioside content and showed that highly ex-
pressed gangliosides of neuroblastoma tumor cells
are shed at a rapid rate.
Shedding of microvesicles might be important in
some physiological and pathophysiological processes
w x37,38 . In atherosclerosis, for example, shedding of
vesicles is thought to be involved in the mineralisa-
w x w xtion processes 39 . Tanimura et al. 39 showed that
a major mechanism in the development of athero-
sclerotic calcification is the deposition of calcium
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phosphate within matrix vesicles which appear to
derive from intimal smooth muscle cells by budding
from their cytoplasmic membranes.
In mammalian cells, newly synthesised ganglio-
sides translocate from the Golgi complex to the
plasma membrane while membrane gangliosides flow
in the opposite direction from the plasma membrane
w xto intracellular organelles 40 . Shedding membra-
nous fragments thus excludes some portions of cell
gangliosides from the turnover pathway. Influx of
cholesterol into the vascular wall might intensify this
process and facilitate the formation of ganglioside
deposits in atherosclerotic lesions. The specific stain-
ing of intimal material around cholesterol crystals
found in the present study can thus be associated with
the destruction of some cells in the intima which in
turn is followed by the release of cellular components
w xinto the extracellular space 41 .
The processes leading to the formation of athero-
sclerotic lesions in the intima, such as influx of lipid
components from plasma, cholesterol incorporation,
changing of cell phenotype and cell destruction, can
all promote the accumulation of GM3 in athero-
w xsclerotic lesions 42 . Shedding GM3 with the mem-
branous fragments, itself depending on an increased
cholesterol content of intimal cells, may influence the
w xchange in cell phenotype 43 , induce cell prolifera-
w xtion 44 and production of antiganglioside antibodies
w x18 . Impregnation of the extracellular matrix with
gangliosides might initiate adhesion and chemotaxis
w x 2q w xof lymphoid cells 45 , binding of Ca 46,47 ,
w xgrowth factors 44 and a number of other processes
promoting the formation of advanced atherosclerotic
plaques.
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